Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrimXMAD:PRM -0.38%83 3-Year Book Growth Rate is 4.80% as of Jun. 2026, which is 7% above its 10-year median of 4.50. GuruFocus rates XMAD:PRM with a GF Score™ of 83/100 and a GF Value™ of €13.76 (Fairly Valued). The stock has 4 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Prim ranks better than 59.21% on this metric.
During the past 12 months, Prim's average Book Value per Share Growth Rate was 3.70% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 4.80% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 4.00% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 3.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Prim was 9.90% per year. The lowest was -2.00% per year. And the median was 4.50% per year.
Prim (XMAD:PRM) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Prim 3-Year Book Growth Rate Related Terms
XMAD:PRM vs ISRG, BDX, MDLN: 3-Year Book Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Prim's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prim 3-Year Book Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prim's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Prim's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 4.80% mean?
Prim (XMAD:PRM) has a 3-Year Book Growth Rate of 4.80% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Prim and its competitors. This is near median its historical median of 4.50. According to the industry distribution chart, Prim ranks #310 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 40.8%.
Is Prim's 3-Year Book Growth Rate too high?
Prim's current 3-Year Book Growth Rate of 4.80% is near median its 10-year median of 4.50. The Medical Devices & Instruments industry median 3-Year Book Growth Rate is 2.30. Prim's value of 4.80% is 108.7% above this industry median. Based on the distribution chart, Prim ranks #310 out of 760 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Prim has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Prim's 3-Year Book Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prim ranks #310 out of 760 companies for 3-Year Book Growth Rate. This puts Prim in the upper half of its industry. The industry median 3-Year Book Growth Rate is 2.30. Prim's value of 4.80% is 108.7% above this benchmark. While the company's 10-year median is 4.50 vs. the industry median of 2.30, Prim has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Book Growth Rate among Medical Devices & Instruments companies is 2.30, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prim's current 3-Year Book Growth Rate of 4.80% is 108.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Prim and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Book Growth Rate is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prim's current 3-Year Book Growth Rate is 4.80%, which is near median its own 10-year median of 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prim stock overvalued right now?
Based on GuruFocus' analysis, Prim (XMAD:PRM) is currently considered Fairly Valued. The stock's GF Value™ is €13.76, compared to a current price of €13.25 — trading 3.7% below its estimated fair value. The current 3-Year Book Growth Rate is 4.80%, which is near median its 10-year median of 4.50 and 108.7% above the Medical Devices & Instruments industry median of 2.30. Prim's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Prim (XMAD:PRM), the current 3-Year Book Growth Rate is 4.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prim (XMAD:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Prim stock appears to be undervalued.
The current stock price of €13.25 is trading 3.7% below its estimated GF Value™ of €13.76.
GuruFocus considers Prim to be Fairly Valued.
Key valuation signals for XMAD:PRM:
3-Year Book Growth Rate: 4.80% (near median its 10-year median of 4.50)
GF Value™: €13.76 vs. price of €13.25 (3.7% below fair value)
Industry Position: 108.7% above the Medical Devices & Instruments median (#310 of 760)
No single metric tells the full story. See the XMAD:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prim SA is engaged in the provision of hospital supplies. The company is in a hospital and orthopedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, geriatrics, as well as daily living aids. Prim work across a division of healthcare units such as Operating Theatres; Pain Management Centres; Plastic Surgery; Endosurgery and Cardiovascular.
83GF Score
Get the complete analysis for XMAD:PRM
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PRM has been successfully added to your 
